Vor Biopharma Inc is a clinical stage cell therapy company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
VOR is expected to report earnings to fall 15.33% to -33 cents per share on March 20
Q4'24
Est.
$-0.34
Q3'24
Est.
$-0.40
Q2'24
Beat
by $0.01
Q1'24
Missed
by $0.06
Q4'23
Beat
by $0.11
The last earnings report on November 07 showed earnings per share of -40 cents, meeting the estimate of -40 cents. With 47.44K shares outstanding, the current market capitalization sits at 108.62M.